Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures
A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.
Sponsor: UCB Pharma SA
This PHASE3 trial investigates Epilepsy and is currently completed. UCB Pharma SA leads this study, which shows 12 recorded versions since 2007 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Sep 2022 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Sep 2018 — Sep 2020 [monthly]
Completed PHASE3
-
Jul 2018 — Sep 2018 [monthly]
Completed PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Sep 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- UCB Pharma SA
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alcorcón, Spain , Angers, France , Bad Berka, Germany , Bangalore, India , Barcelona, Spain , Berlin, Germany , Bernau, Germany , Bialystok, Poland , Biel, Switzerland , Bielefeld, Germany and 61 more locations